Cardiologists at NewYork-Presbyterian/Columbia University Irving Medical Center compared electrocardiographic findings among National Basketball Association (NBA) athletes with other published athlete groups in a new study. The study builds on prior research that established the first large-scale normative cardiac dataset for basketball players (and athletes of similar size as elite basketball players). Results from the new study demonstrated the criteria used to identify athletes at risk for exercise-triggered sudden cardiac death, known as the International Criteria, find a higher rate of false-positive results among NBA athletes. The results indicate a need for additional sport-specific guidelines to differentiate expected cardiac changes from abnormalities.

Toshiba Medical, a Canon Group company, showcased the Aquilion Precision, what it calls the world’s first ultra-high resolution computed tomography system (UHR CT) at the 2017 Radiological Society of North America (RSNA) Annual Meeting, Nov. 26-Dec. 1 in Chicago. The system, which is pending U.S. Food and Drug Administration (FDA) 510(k) clearance, is capable of resolving anatomy as small as 150 microns, providing CT image quality with resolution typically seen only in cath labs. The UHR detector is newly designed to provide more than twice the resolution when compared with today’s CT technology, featuring an all-new detector as well as tube, gantry and reconstruction technologies.

December 6, 2017 — Electronic cigarettes are more frequently used by people who recently quit smoking and alcohol ...

December 6, 2017 — Older women who do not get enough sleep were more likely to have poor cardiovascular health ...

Infant deaths from critical congenital heart disease (CCHD) decreased more than 33 percent in eight states that mandated screening for CCHD using a test called pulse oximetry. In addition, deaths from other or unspecified cardiac causes decreased by 21 percent, according to a recent study.

Fujifilm Medical Systems U.S.A. Inc. announced the expansion of the company's artificial intelligence (AI) development initiative with entry in the U.S. market. The AI development initiative will harness the power of AI to enhance Fujifilm’s imaging and informatics healthcare Synapse portfolio which includes Synapse PACS (picture archiving and communication system), Synapse Cardiovascular and Synapse VNA (vendor neutral archive), among other solutions. The initiative was on display at the 2017 Radiological Society of North America (RSNA) annual meeting, Nov. 26-Dec. 1 in Chicago.